Role of p53 family members p73 and p63 in human hematological malignancies
- PMID: 22497596
- DOI: 10.3109/10428194.2012.684348
Role of p53 family members p73 and p63 in human hematological malignancies
Abstract
p53, mutated in over half of human cancers and about 13% of all hematological malignancies, maintains genomic integrity and triggers cellular senescence and apoptosis of damaged cells. In contrast to p53, the homologs p73 and p63 play critical roles in development of the central nervous system and skin/limbs, respectively. Moreover, dependent on the context they can exert tumor suppressor activities that cooperate with p53. Unlike p53, p73 and p63 are rarely mutated in cancers. Instead, up-regulation of the anti-apoptotic dominant-negative ΔNp73 and ΔNp63 isoforms is the most frequent abnormality in solid cancers. In hematological malignancies the most frequent p73 defect is promoter methylation and loss of expression, associated with unfavorable clinical outcomes. This suggests an essential tumor suppressor role of p73 in blood cells, also supported by genetic mouse models. Many therapeutic approaches aiming to restore p73 activity are currently being investigated. In contrast, the most frequent p63 abnormality is protein overexpression, associated with higher disease grade and poorer prognosis. Surprisingly, although available data are still scarce, the emerging picture is up-regulation of transactivation-competent TAp63 isoforms, suggesting a tumor-promoting role in this context.
Similar articles
-
One, two, three--p53, p63, p73 and chemosensitivity.Drug Resist Updat. 2006 Dec;9(6):288-306. doi: 10.1016/j.drup.2007.01.001. Epub 2007 Feb 6. Drug Resist Updat. 2006. PMID: 17287142 Review.
-
Alterations of p63 and p73 in human cancers.Subcell Biochem. 2014;85:17-40. doi: 10.1007/978-94-017-9211-0_2. Subcell Biochem. 2014. PMID: 25201187 Free PMC article. Review.
-
The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.Histol Histopathol. 2015 May;30(5):503-21. doi: 10.14670/HH-30.503. Epub 2014 Dec 16. Histol Histopathol. 2015. PMID: 25510918 Review.
-
p63 and p73 in human cancer: defining the network.Oncogene. 2007 Aug 9;26(36):5169-83. doi: 10.1038/sj.onc.1210337. Epub 2007 Mar 5. Oncogene. 2007. PMID: 17334395 Review.
-
Differential regulation of p63 and p73 expression.Oncogene. 2003 Aug 28;22(36):5686-93. doi: 10.1038/sj.onc.1206859. Oncogene. 2003. PMID: 12944917
Cited by
-
TAp73 is a central transcriptional regulator of airway multiciliogenesis.Genes Dev. 2016 Jun 1;30(11):1300-12. doi: 10.1101/gad.279836.116. Epub 2016 Jun 2. Genes Dev. 2016. PMID: 27257214 Free PMC article.
-
Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression.Breast Cancer (Auckl). 2019 Feb 21;13:1178223419830982. doi: 10.1177/1178223419830982. eCollection 2019. Breast Cancer (Auckl). 2019. PMID: 30814841 Free PMC article.
-
Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.Dis Markers. 2022 Jun 15;2022:6410113. doi: 10.1155/2022/6410113. eCollection 2022. Dis Markers. 2022. PMID: 35756491 Free PMC article.
-
p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies.Cancers (Basel). 2021 Jun 9;13(12):2885. doi: 10.3390/cancers13122885. Cancers (Basel). 2021. PMID: 34207603 Free PMC article. Review.
-
Epigenetic Control of Infant B Cell Precursor Acute Lymphoblastic Leukemia.Int J Mol Sci. 2021 Mar 18;22(6):3127. doi: 10.3390/ijms22063127. Int J Mol Sci. 2021. PMID: 33803872 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
